T Poynard
Overview
Explore the profile of T Poynard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
324
Citations
7740
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Donath H, Wolke S, Knop V, Hess U, Duecker R, Trischler J, et al.
Can J Gastroenterol Hepatol
. 2023 Mar;
2023:2877350.
PMID: 36941982
Background: Ataxia-telangiectasia (A-T) is a rare autosomal-recessive multisystem disorder characterized by pronounced cerebellar ataxia, telangiectasia, cancer predisposition, and altered body composition. Liver diseases with steatosis, fibrosis, and hepatocellular carcinoma are...
2.
Munteanu M, Tiniakos D, Anstee Q, Charlotte F, Marchesini G, Bugianesi E, et al.
Aliment Pharmacol Ther
. 2016 Aug;
44(8):877-89.
PMID: 27549244
Background: Blood tests of liver injury are less well validated in non-alcoholic fatty liver disease (NAFLD) than in patients with chronic viral hepatitis. Aims: To improve the validation of three...
3.
Houot M, Ngo Y, Munteanu M, Marque S, Poynard T
Aliment Pharmacol Ther
. 2015 Oct;
43(1):16-29.
PMID: 26516104
Background: Blood tests and transient elastography (TE), proposed as alternatives to biopsy for identifying advanced fibrosis (METAVIR-stage-F2 or greater) or cirrhosis, have never been compared using an intention to diagnose...
4.
Boursier J, Ducancelle A, Vergniol J, Veillon P, Moal V, Dufour C, et al.
J Viral Hepat
. 2015 Jul;
22(12):1002-10.
PMID: 26216230
Triple therapy using boceprevir or telaprevir remains the reference treatment for genotype 1 chronic hepatitis C in countries where new interferon-free regimens have not yet become available. Antiviral treatment is...
5.
Friedrich-Rust M, Lupsor M, de Knegt R, Dries V, Buggisch P, Gebel M, et al.
Ultraschall Med
. 2015 May;
36(3):239-47.
PMID: 25970201
Purpose: The aim of the present prospective European multicenter study was to demonstrate the non-inferiority of point shear wave elastography (pSWE) compared to transient elastography (TE) for the assessment of...
6.
Renvoise A, Lemaitre N, Saintenoy G, Benosman H, Geffrier C, Epelboin L, et al.
Int J Infect Dis
. 2015 Apr;
34:122-5.
PMID: 25835101
We report herein a case of bacteremic ascitic fluid infection in a liver transplant patient caused by a strain of Yersinia pseudotuberculosis serogroup I that lost the yersiniabactin core. The...
7.
Desire N, Ngo Y, Franetich J, Dembele L, Mazier D, Vaillant J, et al.
J Viral Hepat
. 2015 Feb;
22(9):718-26.
PMID: 25644062
Hepatitis B (HBV) virus infection is characterized by the overproduction of subviral particles (SVP) over infectious Dane particles (VP). Precise regulation of the ratio between these forms is unknown, but...
8.
Rudler M, Cluzel P, Corvec T, Benosman H, Rousseau G, Poynard T, et al.
Aliment Pharmacol Ther
. 2014 Sep;
40(9):1074-80.
PMID: 25230051
Background: Early-TIPSS (transjugular intrahepatic portosystemic shunt) placement may improve rebleeding and reduce 1-year mortality, compared to standard management in high-risk patients with cirrhosis and variceal bleeding. Aim: To obtain external...
9.
Rueger S, Bochud P, Dufour J, Mullhaupt B, Semela D, Heim M, et al.
Gut
. 2014 Sep;
64(10):1605-15.
PMID: 25214320
Objective: The natural course of chronic hepatitis C varies widely. To improve the profiling of patients at risk of developing advanced liver disease, we assessed the relative contribution of factors...
10.
Perazzo H, Munteanu M, Ngo Y, Lebray P, Seurat N, Rutka F, et al.
Aliment Pharmacol Ther
. 2014 Sep;
40(9):1081-93.
PMID: 25186086
Background: In cardiometabolic disorders, non-alcoholic fatty liver disease is frequent and presumably associated with increased mortality and cardiovascular risk. Aim: To evaluate the prognostic value of non-invasive biomarkers of liver...